 "Serum Institute to apply for emergency use of Covid vaccine in next 2 weeks")
Serum Institute of India (SII), the world's largest vaccine producer, is in active discussions with the Indian government on pricing and distribution of potential COVID-19 vaccines, said its Chief Executive Adar Poonawalla on Saturday.
Poonawalla said in the next few weeks SII plans to apply for emergency use authorization for AstraZeneca's COVID-19 vaccine candidate that he described as a "very good" option.
His comments come following Indian Prime Minister Narendra Modi's visit to the Serum Institute of India's sprawling campus in the western city of Pune.
Serum Institute, the world's largest vaccine manufacturer, has partnered with global players including AstraZeneca and Novavax Inc to run domestic trials on their vaccine candidates and produce the vaccines if they secure approvals.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app